Commencement 2009: Changing the Way We Look at Drug Manufacturing, Malaria, and Spinal Cord Injury
Photo Credit: Rensselaer/Mark
McCarty
|
During her time at Rensselaer as a doctoral student in
biochemistry and biophysics, Melissa Kemp has worked on
research that has drawn international attention and could help
protect the lives of millions of people. With 10 publications
and a submitted patent, the young scientist has already helped
develop research that has implications for drug safety, spinal
injury repair, and malaria prevention.
Following the death of more than 80 people around the world
from contaminated batches of the blood thinner heparin, Kemp
went to work in the lab of Robert Linhardt, one of the foremost
experts on heparin and the Ann and John H. Broadbent Jr. ’59
Senior Constellation Professor of Biocatalysis and Metabolic
Engineering at Rensselaer. Linhardt was among the scientists to
discover the contamination known as oversulfated chondroitin
sulfate, which has a structure so similar to heparin it was
nearly undetectable. Kemp was involved in studying the
detection of contaminant using five methods commonly utilized
by drug manufacturers. Kemp and collaborators found that two of
these methods would fail to accurately detect the sneaky
contaminant. She said she hopes that companies using these
methods take extra precautions in detecting the presence of
contaminant.
Kemp also worked with Linhardt to study heparin-protein
interactions using a technique called surface plasmon resonance
(SPR). She worked on the formulation of a synthetic heparin by
screening its interaction with other proteins, which was one of
the first steps in making a purely synthetic heparin.
Conventional heparin is derived from animal tissues, while
synthetic heparin is considered a safer alternative as it’s
made completely in a controlled laboratory setting.
“These experiments provided proof of concept that heparin
could in fact be created chemoenzymatically, meaning that we
could develop a batch of heparin in the lab without using
animal sources,” she said.
In addition to her work on heparin, Kemp remains heavily
involved in research to stop the spread of malaria at its
source. The findings could help stop any man, woman, or child
from needing to take a drug. Kemp again worked alongside
Linhardt and colleagues to isolate a complex carbohydrate
called heparan sulfate in mosquitoes, which Linhardt had
previously discovered to be the transporter of the disease in
the human body. The team wanted to see if heparan sulfate was
also present in the mosquito and displayed the same behavior of
interaction as the heparan sulfate in humans.
Kemp helped lead the effort to determine the binding
activity of the carbohydrate in the organism and how it
developed and migrated in the mosquito. She discovered that
heparan sulfate was also present in the disease-spreading
organs of the mosquito, including the salivary glands, and has
the ability to interact with the critical protein on the
parasite. She is currently working to determine other molecules
that are directly involved in the heparan sulfate-protein
interactions in the organism in the hopes of developing a
method or drug that could stop its progress and prevent the
spread of the disease directly in the mosquito.
Kemp is also working with nanotechnologies to help heal
spinal cord injury. In particular, she is using nano-supports
to immobilize and stabilize a protein known as chondroitinase.
Chondroitinase has been previously discovered to improve spinal
cord injury in animal models, but thus far it has been
difficult to use even experimentally because it is highly
unstable after only a short period of time. Kemp and her
collaborators hope that the nano-support will keep the material
more stable and improve its localization in the body.
Kemp grew up in Milton, N.Y., across the river from
Poughkeepsie with her older brother. She received a bachelor’s
in computer science from Pace University. She is a member of
several high-level scientific societies and is currently
looking for a post-doctoral position in molecular biology to
supplement her experience in chemistry. She said she
hopes to build a career working in the laboratory
environment.
|
Published
May 15,
2009 |
Contact: Gabrielle DeMarco
Phone: (518) 276-6542
E-mail: demarg@rpi.edu |
|